Glenmark Pharmaceuticals has informed that it attached media release dated October 11, 2021 titled ‘Glenmark launches Tavulus® for COPD treatment in Spain, becoming one of the first companies to launch a bioequivalent version of the dry powder inhaler’.
The above information is a part of company’s filings submitted to BSE.